Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia

Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia

Avatrombopag is an oral thrombopoietin receptor agonist (TPO-RA) that was approved in the US in 2019 for treatment of chronic immune thrombocytopenia (ITP). This post hoc analysis of the pivotal phase III study (NCT01438840) of avatrombopag in adult patients with ITP evaluated platelet count respons...

Full description

Bibliographic Details
Main Authors: Shivi Jain, Terry Gernsheimer, Scott Kolodny, Chelsea Bernheisel, Michael Vredenburg, Sandhya R. Panch
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Platelets
Subjects:
durability of response
immune thrombocytopenia
post hoc analysis
thrombopoietin receptor agonist
Online Access:http://dx.doi.org/10.1080/09537104.2023.2195016

Internet

http://dx.doi.org/10.1080/09537104.2023.2195016

Similar Items